This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia (NCT02625844), a registered phase not stated study. The primary outcome is Average Observed Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents (ESAs).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT02625844 |
| Phase | Phase not stated |
| Condition | Renal Anemia of Chronic Kidney Disease |
| Allocation | Not Stated |
| Design model | Not Stated |
| Masking | Not Stated |
| Enrollment | 110 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Hoffmann-La Roche |
| Results posted | Yes |
2. Clinical Question
Population
Patients with end stage renal disease receiving care in hemodialysis centers in Croatia, with health care personnel performing anemia-management tasks. The registry lists renal anemia of chronic kidney disease as the condition. The total enrollment was 110; the numbers assigned to each treatment-use group are not reported in the registry record.
Intervention
The study describes personnel tasks for patients using monopegylated epoetin beta, also named Mircera in the registry summary. The tasks include preparation, distribution and administration of erythropoiesis-stimulating agents. The registry lists no intervention, so this is not a treatment assignment described as a trial intervention.
Comparator
Personnel time for patients using monopegylated epoetin beta is considered alongside time for patients using other erythropoiesis-stimulating agents. The study summary describes determining average time for the same number of patients in each group, but actual group sizes and the method for selecting or matching patients are not reported in the registry record.
Primary question
How much health care personnel time, expressed in hours/year, is observed for anemia management with erythropoiesis-stimulating agents? The stated tasks are preparation, distribution and administration. The registry identifies a timeframe of up to 3 months, but numerical outcome values and the method for expressing observations as hours/year are not reported in the registry record.
3. Trial Design
This completed study is described as a time-and-motion survey of anemia-management activity in hemodialysis units in Croatia. Its stated purpose was to document the time health care personnel spent preparing, distributing and administering erythropoiesis-stimulating agents for patients with end stage renal disease. The registry lists enrollment of 110 and gives a start date of 2011-09 and primary completion date of 2012-08.
The comparison is between patients using monopegylated epoetin beta and patients using other erythropoiesis-stimulating agents. These are groups defined by the treatment patients were using, not arms described as randomized assignments. The registry lists the intervention as “No intervention.” Allocation is not stated, and the record does not describe a like-for-like control comparison. The intended comparison of the same number of patients in each group is stated in the summary; actual group sizes and the selection process are not reported in the registry record.
The study also aimed to obtain qualitative information about changes in practice patterns that may have occurred with the introduction of monopegylated epoetin beta. The registry does not describe how that qualitative information was collected or analyzed. The primary outcome timeframe is up to 3 months. Details of the observation schedule, participating centers, staff roles, data collection instrument and analysis plan are not reported in the registry record.
The sponsor is Hoffmann-La Roche. The registry marks the study completed, but does not report numerical results for the primary measure or analyses comparing the groups. The record therefore supports describing the study objective and design features, but not estimating the observed difference in personnel time.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Patient disposition information was unavailable. Therefore, all participants are represented in one arm.
Overall Study
| Stage | Erythropoiesis Stimulating Agents (ESAs) |
|---|---|
| STARTED | 110 |
| COMPLETED | 110 |
| NOT COMPLETED | 0 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Erythropoiesis Stimulating Agents (ESAs) |
|---|---|---|
| Participants analysed | 110 | |
| Age, Customized: >/= 18 years | participants | 110 |
| Sex: Female, Male: Female | Participants | NA |
| Sex: Female, Male: Male | Participants | NA |
6. Primary Endpoint
The registry lists the primary outcome as Average Observed Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents (ESAs), measured over Up to 3 months.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | hours/year |
| Endpoint classification | not reduced to a single comparison |
The primary measure is average observed health care personnel time for anemia management with erythropoiesis-stimulating agents, expressed in hours/year. The registry’s description includes time for preparation, distribution and administration. It lists a measurement timeframe of up to 3 months.
This measure is relevant to the study objective because it focuses on the staff time associated with the management process, rather than on a patient health outcome. Describing time spent on specific tasks can help characterize the operational workload associated with the different treatment-use groups. It can also provide a basis for a descriptive comparison, if group results and appropriate details about how observations were collected are available.
The registry does not report the numerical average in either group, a measure of variability, or a between-group estimate. It also does not explain how observations made over up to 3 months were expressed in hours/year, or how the average was formed across patients, staff members, tasks or centers. Without these details and results, the endpoint can be described, but its observed value and comparative precision cannot be assessed.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The record identifies one primary outcome measure, but gives no numerical results for it and reports no analyses. Consequently, the size and direction of any observed difference in personnel time cannot be established from the registry record. There is no reported estimate, uncertainty interval or test result to interpret. The study’s stated intention to compare time for the same number of patients does not establish the actual group sizes or show that the groups were comparable.
The design is described as observational: the registry lists “No intervention,” and allocation is not stated. The comparison concerns patients using different erythropoiesis-stimulating agents, rather than treatment groups assigned by a described random process. In general, observational group comparisons can reflect both the exposure of interest and differences between the groups or their settings. The registry does not report information that would establish whether such factors were measured, balanced or adjusted for. It is therefore not possible to interpret an unreported contrast as an isolated effect of one agent on staff time.
The primary outcome is measured in hours/year, while the listed timeframe is up to 3 months. The record does not explain the relationship between the observation period and the annual unit. Any annualization procedure, if used, is not reported in the registry record. This matters because the interpretation of a time rate depends on how observation windows and task records are translated into the stated unit.
The enrollment count of 110 describes the overall study, not the number of observations contributing to each group or endpoint. The registry does not report missing measurements, exclusions from the primary analysis, or the number of personnel, patients or centers represented in the result. These omissions limit assessment of representativeness and precision.
Accordingly, the posted record establishes a study question and a primary measure, not a quantitative finding. It does not support a conclusion about which group required more staff time, how large any difference might have been, or how precisely it was estimated. It also does not establish whether practice patterns changed; that was an additional qualitative objective, and corresponding findings are not reported in the registry record.
9. Statistical Methods Explained
The registry describes an observational time-and-motion survey, with personnel time as the subject of measurement. It does not report a statistical analysis plan. The explanations below describe general statistical concepts relevant to this kind of outcome; they should not be read as methods confirmed to have been used in the study.
What does an average represent?
In general, an average summarizes a set of observed values with one measure of central tendency. For personnel time, those values might be recorded task durations or totals over an observation window. The interpretation depends on the unit of analysis and the way observations are combined. A mean across patients, a mean across staff members and a mean across centers answer different questions when their contributions differ. The registry identifies an average in hours/year but does not report the individual observations, aggregation method or weighting approach.
Why does the unit and observation window matter?
The stated timeframe is up to 3 months, while the endpoint unit is hours/year. In general, an annual rate can be formed by relating observed time to an observation period, but the exact procedure and its assumptions matter. For example, translating a limited observation window into a longer-term rate may depend on whether observed activity is representative of activity over the longer period. No annualization procedure, repeat-measurement schedule or adjustment for variation over time is reported in the registry record. The annual unit should therefore be treated as the reported endpoint definition, not as evidence of how the conversion was performed.
How should a group comparison be interpreted?
In general, an unadjusted comparison describes the observed outcomes in the groups as recorded. An adjusted comparison attempts to account for specified differences between groups using a statistical model. The registry provides no group-level outcome values, no comparative estimate and no analysis details. It does not report whether the intended equal-size comparison was achieved, or whether any adjustment was performed. No adjusted or unadjusted effect can be reconstructed from the record.
Because allocation is not stated and the registry lists no intervention, the groups should be understood as treatment-use groups rather than randomized arms. In general, treatment-use groups may differ in ways related to the treatment received or to the setting in which care is delivered. A valid interpretation would need details on how patients and centers entered each group and how potential differences were handled. Those details are not reported in the registry record.
What would precision information add?
In general, a confidence interval gives a range of estimates compatible with the observed data under the model used. Its width conveys precision: a narrower interval indicates greater precision under that model, while a wider interval indicates greater uncertainty. A confidence interval is not reported for this outcome. Nor are a standard deviation, standard error, or other dispersion measure reported. The average alone, even if it were available, would not describe how much time varied across observations.
Time data can sometimes be asymmetric, with many short tasks and a smaller number of long tasks. In general, the distribution and the unit of observation help determine whether a mean adequately describes typical workload and whether standard statistical methods are suitable. The registry gives no distributional information. It is not possible to determine whether time values were skewed, whether observations were repeated within staff or centers, or whether an analysis accounted for such clustering. If observations from the same staff member or center are related, treating them as independent can make uncertainty estimates too small; this is a general consideration, not a reported feature of the analysis.
How do planning illustrations differ from study results?
Sample-size planning illustrations based on an observed effect are not the study’s original design justification and are not observed power. The stated illustration assumptions are a two-sided significance level of 0.05, equal allocation, a normal approximation, and a target effect defined as a stated fraction of the observed effect. The record does not report a protocol-based sample-size justification or the original design assumptions. Since the outcome values and any observed effect are not reported in the registry record, no numerical planning illustration can be interpreted from the record alone. Such calculations, when available, describe hypothetical participant requirements under their assumptions; they do not show the probability that the completed study detected an effect.
For this outcome, planning counts would refer to participants per arm, rather than total events. That distinction is general: sample-size calculations depend on the endpoint and design. Planning estimates also rely on assumptions about variability, target effect and analysis. They do not substitute for an uncertainty interval around a study’s actual result, and they do not repair limitations in group comparability or outcome measurement.
Overall, the registry supports a methodological description of the question and outcome, but not a statistical reconstruction. Numerical estimates, uncertainty, model choices and diagnostics are not reported in the registry record. Any more detailed account of how the primary measure was analyzed would require information beyond the record.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists one outcome measure and reports zero analyses. The record does not describe a prespecified statistical analysis plan, hypothesis-testing strategy, interim analyses or adjustment for multiple comparisons. It is therefore not possible to determine whether multiple endpoints, subgroups, task categories or time points were considered in the study’s analyses. The presence of a single listed primary measure does not establish that no other analyses were performed; those details are not reported in the registry record.
In general, multiplicity arises when several statistical questions are tested or estimates selected. Considering many comparisons can increase the chance that an apparently notable result arises by chance. Whether and how to address that issue depends on the analysis plan and the set of questions examined. The record does not provide enough information to assess multiplicity for this study.
Missing-data methods and analysis populations are also not described. The registry does not report how many observations were unavailable, whether any participants or centers were excluded from the primary measure, or how incomplete time records were handled. It does not identify a full analysis population or a subset used for the primary outcome. These omissions make it impossible to assess whether the reported enrollment corresponds to the population contributing to an analysis.
In general, missing observations can affect both the estimate and its precision, especially if the likelihood of missingness is related to the amount of time recorded or to group membership. No such pattern can be assessed from the registry record. The study’s enrollment of 110 should not be treated as the number analyzed for the primary endpoint.
11. What the Result Does, and Does Not, Mean
The study addresses a practical measurement question: how much health care personnel time is associated with anemia-management tasks for patients using erythropoiesis-stimulating agents in Croatian hemodialysis centers. The endpoint covers preparation, distribution and administration and is expressed in hours/year. The stated comparison is between use of monopegylated epoetin beta and use of other agents.
What the record does not establish is the observed time in either group or the amount and precision of any difference. No numerical primary outcome results, group sizes, variability estimates or comparative analyses are reported in the registry record. A reader therefore cannot tell from this record whether the groups had similar or different measured times, or whether an apparent difference would be precise.
The comparison should not be interpreted as a randomized treatment effect. Allocation is not stated, and the record lists no intervention. In general, differences in observed time between treatment-use groups may reflect differences in patients, staff, centers, local procedures or measurement as well as differences related to the agent in use. The registry does not report enough design or analysis detail to distinguish among these possibilities.
The record also does not establish that practice patterns changed after the introduction of monopegylated epoetin beta. That is described as a qualitative objective, but the methods and findings for it are not reported in the registry record. Nor does the primary measure describe patient clinical outcomes; it is a personnel-time measure.
Thus, the defensible interpretation is limited to the study’s purpose, setting, stated comparison and endpoint definition. The completed status and enrollment count do not substitute for outcome results. Claims about workload differences, operational savings, clinical effects or changes in practice would go beyond what the registry record reports.
12. Why This Trial Matters Statistically
Personnel time is a distinct type of outcome from clinical response or safety. Measuring task time can frame a question about how care is organized and the workload associated with delivering a service. A time-and-motion survey can therefore be relevant to clinical operations, provided the observations and comparison are described well enough to interpret.
This study’s stated focus on preparation, distribution and administration identifies concrete activities rather than an abstract measure of resource use. Its comparison of treatment-use groups also illustrates a common statistical challenge: an operational difference between groups is not automatically attributable to the treatment category when assignment and comparability are not established. Clear descriptions of sampling, observation, group formation and analysis are important for separating a descriptive contrast from a causal claim.
The endpoint also illustrates why units and time windows deserve attention. Hours/year and an observation period of up to 3 months appear together in the registry description, but the conversion procedure is not reported. Understanding the denominator and aggregation rule is essential when interpreting rates of staff time.
The record’s limited numerical reporting makes another statistical point: a study objective and an enrollment count do not convey an effect estimate or its precision. Without group outcomes and uncertainty measures, readers cannot judge the magnitude of a contrast. The record remains useful for identifying the intended operational question, while leaving the empirical comparison unresolved in the registry record.
13. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The main limitation for statistical interpretation is that the registry record does not report numerical results for the primary endpoint, despite listing one outcome measure. It also reports zero analyses. There is no group-specific average, variability measure, effect estimate or uncertainty interval with which to assess magnitude or precision.
The record gives an overall enrollment of 110 but does not report group sizes or analysis populations. Although the summary describes comparing the same number of patients in each treatment-use group, the actual numbers and method for forming the groups are not reported in the registry record. Allocation is not stated, and the registry identifies no intervention. The comparison is therefore not documented as randomized or as a like-for-like control comparison.
Measurement details are limited. The primary outcome has units of hours/year and a timeframe of up to 3 months, but the record does not explain how the time observations were converted or aggregated. It does not describe the observation instrument, staff roles, number of centers, repeat observations, handling of unusually long durations, or whether records were checked for completeness. These omissions constrain interpretation of measurement validity and representativeness.
Statistical methods, missing-data handling, multiplicity procedures and analysis populations are not reported in the registry record. The stated qualitative objective concerning practice patterns is also not accompanied by reported methods or findings. These limitations are specific to what the registry documents; they do not establish what may or may not have been done outside the record.
14. Related Tutorials
15. Related Statistical Calculators
16. Sources
- ClinicalTrials.gov: Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia — NCT02625844.
- Registry record last updated 2016-03-03; status last verified 2016-02.
- Results first posted 2016-03-03.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
17. Record Summary
NCT02625844 is a completed time-and-motion survey concerning anemia management in hemodialysis centers in Croatia. It lists enrollment of 110, a start date of 2011-09, primary completion in 2012-08 and Hoffmann-La Roche as sponsor. The condition is renal anemia of chronic kidney disease.
The study’s stated comparison concerns health care personnel time for patients using monopegylated epoetin beta versus other erythropoiesis-stimulating agents. Its primary measure is average observed personnel time in hours/year for preparation, distribution and administration, with a timeframe of up to 3 months. The registry lists no intervention and does not state allocation.
Numerical results, group sizes, analysis methods and precision estimates are not reported in the registry record. The registry also describes a qualitative objective about possible changes in practice patterns, without reporting its methods or findings. Accordingly, the record documents the study question and endpoint, but not a quantitative conclusion about the comparison.